Medicure Inc V.MPH

under the Creating Hope Act

[Checkout]

passed in 2012, the FDA grants a Rare Pediatric Disease Designation for serious and life threatening diseases that primarily affect children. If a new drug application for MC1 for patients with PNPO defficiency ia approved, the company may be eligible to receive a priority review voucher from the FDA. This voucher will cover the cost to research the drug, test the drug, market the drug and can be upwards of 100 to 200 million US dollars.

Otherwise pharma would not try to solve these rare conditions for children.

[tylerreddick]

You are funny, you endlessly pump a krap stock that eventually goes belly up, then move on to this one to do the same?  Did you even own MRS, or are you getting paid to post this garbage?

[Winnipeg40]

Worst run Company on the TSX...Can you imagine Friesen buys a Co. for $10 Million US, it goes to 0 in a year...and he is still running the Company.....I did research....not ONE of his many Companies has ever made money....yet,  he is very wealthy with a huge Compound in Florida and a Rolls Royce.....I am sure I dont have to tell you how that would happen.  His Church always appreciated